Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 2/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22650436 | 0.76 | RPS6KA5 (0.34) | SCN5ARPS6KA5MAPTPOLBCASP6 | |
| SCHEMBL22650356 | 0.74 | SCN5A (0.39) | SCN5ARPS6KA5SMN1; SMN2 | |
| SCHEMBL22650740 | 0.74 | RPS6KA5 (0.32) | RPS6KA5SMN1; SMN2 | |
| SCHEMBL15229110 | 0.73 | ADORA2B (0.44) | MAPTDYRK1A | |
| SCHEMBL15577176 | 0.72 | BTK (0.46) | MAPTBTK | |
| SCHEMBL22650908 | 0.72 | CAMKK1 (0.38) | SCN5ARPS6KA5MAPTPOLBCASP6 | |
| SCHEMBL15639555 | 0.71 | KMO (0.41) | SCN5APOLB | |
| SCHEMBL3758203 | 0.71 | KDM4E (0.52) | RPS6KA5MAPTSMN1; SMN2 | |
| SCHEMBL19078912 | 0.71 | MAPT (0.42) | MAPTSMN1; SMN2BTK | |
| SCHEMBL31334102 | 0.71 | MAPT (0.42) | MAPTSMN1; SMN2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040446-A | CDK inhibitors | 基因泰克公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3966213-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | SCN5A 3231/4885RPS6KA5 342/4885PIK3CD 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.